Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith M Gottwein

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Scientific Reports|December 4, 2018
High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antiviralsAnne F Pihl, Anna F Offersgaard, Christian K Mathiesen, et al.
Journal of Virology|May 22, 2015
Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based RecombinantChristian K Mathiesen, Jannick Prentoe, Luke W Meredith, et al.
Journal of Virology|December 24, 2010
Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutationsTroels K H Scheel, Judith M Gottwein, Thomas H R Carlsen, et al.
Gastroenterology|December 25, 2017
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape VariantsJudith M Gottwein, Long V Pham, Lotte S Mikkelsen, et al.
Journal of Virology|December 3, 2010
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralizationJannick Prentoe, Tanja B Jensen, Philip Meuleman, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2013
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a virusesJudith M Gottwein, Sanne B Jensen, Yi-Ping Li, et al.
Hepatology (Baltimore, Md.)|January 17, 2009
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugsJudith M Gottwein, Troels K H Scheel, Tanja B Jensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 16, 2008
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralizationTroels K H Scheel, Judith M Gottwein, Tanja B Jensen, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2016
Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life CycleStéphanie B N Serre, Sanne B Jensen, Lubna Ghanem, et al.
Scientific Reports|October 2, 2020
Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccineKeven Lothert, Anna F Offersgaard, Anne F Pihl, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Scientific Reports|December 4, 2018
High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antiviralsAnne F Pihl, Anna F Offersgaard, Christian K Mathiesen, et al.
Journal of Virology|May 22, 2015
Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based RecombinantChristian K Mathiesen, Jannick Prentoe, Luke W Meredith, et al.
Journal of Virology|December 24, 2010
Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutationsTroels K H Scheel, Judith M Gottwein, Thomas H R Carlsen, et al.
Gastroenterology|December 25, 2017
Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape VariantsJudith M Gottwein, Long V Pham, Lotte S Mikkelsen, et al.
Journal of Virology|December 3, 2010
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralizationJannick Prentoe, Tanja B Jensen, Philip Meuleman, et al.
Antimicrobial Agents and Chemotherapy|January 1, 2013
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a virusesJudith M Gottwein, Sanne B Jensen, Yi-Ping Li, et al.
Hepatology (Baltimore, Md.)|January 17, 2009
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugsJudith M Gottwein, Troels K H Scheel, Tanja B Jensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 16, 2008
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralizationTroels K H Scheel, Judith M Gottwein, Tanja B Jensen, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2016
Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life CycleStéphanie B N Serre, Sanne B Jensen, Lubna Ghanem, et al.
Scientific Reports|October 2, 2020
Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccineKeven Lothert, Anna F Offersgaard, Anne F Pihl, et al.
Pageof 6